Zacks Investment Research upgraded shares of Catalent (NYSE:CTLT) from a hold rating to a buy rating in a research note released on Tuesday morning. Zacks Investment Research currently has $49.00 price target on the stock.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Several other research firms also recently weighed in on CTLT. Goldman Sachs Group assumed coverage on Catalent in a report on Wednesday, January 24th. They set a buy rating and a $50.00 price objective on the stock. Royal Bank of Canada set a $48.00 price objective on Catalent and gave the company a buy rating in a report on Monday, February 5th. Stephens downgraded Catalent from an overweight rating to an equal weight rating in a report on Tuesday, February 6th. Needham & Company LLC reissued a hold rating on shares of Catalent in a report on Monday, October 23rd. Finally, Bank of America raised their price objective on Catalent from $47.00 to $49.00 and gave the company a buy rating in a report on Tuesday, February 6th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $45.70.
Shares of Catalent (NYSE CTLT) opened at $42.48 on Tuesday. The company has a current ratio of 2.22, a quick ratio of 1.78 and a debt-to-equity ratio of 2.66. Catalent has a twelve month low of $27.48 and a twelve month high of $47.87. The firm has a market capitalization of $5,760.00, a price-to-earnings ratio of 77.24, a P/E/G ratio of 2.49 and a beta of 1.47.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.10. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The company had revenue of $606.30 million for the quarter, compared to the consensus estimate of $565.05 million. During the same quarter last year, the business posted $0.27 EPS. Catalent’s revenue for the quarter was up 25.3% on a year-over-year basis. research analysts forecast that Catalent will post 1.53 earnings per share for the current year.
In other Catalent news, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total transaction of $7,189,365.96. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.70% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in CTLT. American Century Companies Inc. lifted its holdings in Catalent by 755.3% during the 4th quarter. American Century Companies Inc. now owns 2,631,643 shares of the company’s stock worth $108,108,000 after buying an additional 2,323,971 shares during the period. Eagle Asset Management Inc. lifted its holdings in Catalent by 290.9% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,153,710 shares of the company’s stock worth $47,636,000 after buying an additional 858,600 shares during the period. Redmile Group LLC lifted its stake in shares of Catalent by 464.2% in the 4th quarter. Redmile Group LLC now owns 833,063 shares of the company’s stock valued at $34,222,000 after purchasing an additional 685,400 shares during the period. Carillon Tower Advisers Inc. acquired a new position in shares of Catalent in the 4th quarter valued at about $27,561,000. Finally, Emerald Advisers Inc. PA lifted its stake in shares of Catalent by 1,072.2% in the 3rd quarter. Emerald Advisers Inc. PA now owns 604,207 shares of the company’s stock valued at $24,120,000 after purchasing an additional 552,663 shares during the period. 99.82% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/21/catalent-ctlt-upgraded-to-buy-at-zacks-investment-research.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.